Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
| Revenue (TTM) | $890.78M |
| Gross Profit (TTM) | $423.71M |
| EBITDA | $69.81M |
| Operating Margin | 9.71% |
| Return on Equity | 7.36% |
| Return on Assets | 2.71% |
| Revenue/Share (TTM) | $2.61 |
| Book Value | $1.44 |
| Price-to-Book | 6.56 |
| Price-to-Sales (TTM) | 3.67 |
| EV/Revenue | 4.13 |
| EV/EBITDA | 50.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 22.30% |
| Shares Outstanding | $339.78M |
| Float | $273.53M |
| % Insiders | 0.12% |
| % Institutions | 1.13% |
Volatility is currently contracting
Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chain control, therapeutic expansion and a target to transition toward earnings growth beginning in 2028.
Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precision Medicine up 30% YoY; Pixclara approval and pipeline advancements offer additional growth catalysts. The ITM acquisition, valued at $1.65 billion with up to $700 million in contingent payments, is expected to deliver $50 million in synergies and meaningful EBITDA from 2027.
The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.
MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce entering into a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) (“Telix”), a commercial-stage global radiopharmaceutical company. The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen (“PSMA”) targeting PET molecular imaging technologies, Gozellix® and Illuccix® 1, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO® platform across the prostate care continuum.
MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.
IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics
The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TLX and any ticker you trade — then tracks every position and per-strategy win rate.
